Gilead Sciences, Inc. (GILD)
149.81
+0.20
(+0.13%)
USD |
NASDAQ |
Sep 03, 11:05
Gilead Sciences Research and Development Expense (TTM) : 5.943B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.943B |
| March 31, 2026 | 5.703B |
| December 31, 2025 | 5.688B |
| September 30, 2025 | 5.734B |
| June 30, 2025 | 5.785B |
| March 31, 2025 | 5.683B |
| December 31, 2024 | 5.814B |
| September 30, 2024 | 5.718B |
| June 30, 2024 | 5.792B |
| March 31, 2024 | 5.843B |
| December 31, 2023 | 5.823B |
| September 30, 2023 | 5.857B |
| June 30, 2023 | 5.577B |
| March 31, 2023 | 5.28B |
| December 31, 2022 | 5.006B |
| September 30, 2022 | 5.483B |
| June 30, 2022 | 5.451B |
| March 31, 2022 | 5.483B |
| December 31, 2021 | 5.362B |
| September 30, 2021 | 4.848B |
| June 30, 2021 | 4.859B |
| March 31, 2021 | 5.024B |
| December 31, 2020 | 5.07B |
| September 30, 2020 | 5.457B |
| June 30, 2020 | 9.289B |
| Date | Value |
|---|---|
| March 31, 2020 | 9.15B |
| December 31, 2019 | 9.106B |
| September 30, 2019 | 8.337B |
| June 30, 2019 | 4.286B |
| March 31, 2019 | 4.318B |
| December 31, 2018 | 4.198B |
| September 30, 2018 | 4.046B |
| June 30, 2018 | 3.896B |
| March 31, 2018 | 3.568B |
| December 31, 2017 | 3.562B |
| September 30, 2017 | 3.792B |
| June 30, 2017 | 3.827B |
| March 31, 2017 | 4.047B |
| December 31, 2016 | 4.381B |
| September 30, 2016 | 3.93B |
| June 30, 2016 | 3.85B |
| March 31, 2016 | 3.517B |
| December 31, 2015 | 2.948B |
| September 30, 2015 | 3.210B |
| June 30, 2015 | 3.098B |
| March 31, 2015 | 2.926B |
| December 31, 2014 | 2.822B |
| September 30, 2014 | 2.344B |
| June 30, 2014 | 2.228B |
| March 31, 2014 | 2.162B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.907B |
| AbbVie, Inc. | 9.714B |
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| Amgen, Inc. | 7.638B |
| Biogen, Inc. | 1.736B |